Gilead Signs an Exclusive Worldwide License Agreement with Durect for its HIV and Hepatitis B Products

Shots:

• Durect to receive $25M up front, ~$145M milestones including ~$75M for development & regulatory and ~$70M on sales plus royalties on sales of products. Gilead to get exclusive WW rights to develop and commercialize a long-acting injectable HIV product based on Durect’s SABER technology
• Gilead also has an exclusive right to access Durect’s SABER platform for HIV and Hepatitis B Virus with an option to license SABER-based products for HIV and HBV. If the option is exercised, Gilead will pay $150M/product in up front, development, regulatory and sales-based milestones plus royalties on sales 
• Durect’s SABER Technology (Sucrose acetate isobutyrate extended release) is used to provide sustained release of long-acting injectable products. Posimir (bupivacaine extended release solution) is locally acting, non-opioid analgesic based on SABER Technology

Click here to read full press release/ article | Ref: Durect | Image: Bastiaan Aalbersberg